159results about How to "Reduce infectivity" patented technology

Nanoemulsion compositions with low toxicity that demonstrate broad spectrum inactivation of microorganisms or prevention of diseases are described. The nanoemulsions contain an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants. Methods of making nanoemulsions and inactivating pathogenic microorganisms are also provided.

A fluid-borne (e.g., water, air) biological and chemical hazard detection and treatment system can include sensors (e.g., flow rate, contaminant detectors), treatment using ultraviolet laser-emitted light, can be microprocessor controlled and can communicate and be controlled over data networks. Treatment and detection systems can be deployed at various stages along a fluid distribution system, allowing for protection coverage and redundancy. During treatment, fluid enters into and / or passes through a “treatment area” wherein the fluid is subjected to light emanating from a laser at wavelengths within the ultraviolet range. DNA for microorganisms contained within fluid (including blood) are reactive to laser light as they pass through treatment areas and are rendered un-infective. Treatment systems can be staged in close proximity, providing more than one treatment area and associated light sources to a fluid stream. Such staging can provide for concentrated redundancy prior to its delivery to the intended point of use.

Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization of infectivity and inactivation of functionally essential events in the life cycle of the virus. The antibodies recognize viral epitopes which fail to elicit an immune response in man when encountered through infection or naturally through the environment. In a preferred embodiment, the invention provides compositions and methods useful in the treatment and diagnosis of human immunodeficiency virus (HIV) infections.

Hybrid peptides capable of binding a blood borne virus to a red cell, comprising a viral binding peptide component and a malaria merozoite red cell peptide binding component.

Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases such as SARS, in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. The present invention provides delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism or, in case of a therapeutic vaccine, to treat or alleviate infection against the lipid-containing infections viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and / or one or more types of virus.

Nanoemulsion compositions with low toxicity that demonstrate broad spectrum inactivation of microorganisms or prevention of diseases are described. The nanoemulsions contain an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants. Methods of making nanoemulsions and inactivating pathogenic microorganisms are also provided.

A method of treating viral infection, such as viral infection caused by a virus of the Coronaviridae family, is provided. A composition having at least oleandrin is used to treat viral infection.

A method for treating biological tissue, particularly meats for human consumption, so as to sanitize the tissue, is described. The method inactivates microorganisms and pathogenic prions (proteins) in the tissue.

The immunoadhesions of the present invention are useful in treating rhinovirus infections. The immunoadhesions contain a chimeric ICAM molecule and may optionally also contain J chain and secretory compounds. The chimeric ICAM molecule is a fusion protein that has a rhinovirus receptor protein linked to an immunoglobulin protein. This invention also includes the greatly increased and improved method of producing immunoadhesions in plants. Each of the components of an immunoadhesin is produced in a plant cell and thereby assembles within the plant cell. This method of producing the immunoadhesions of the present invention results in the efficient and economic production of these molecules. The present invention also contemplates the production of immunoadhesions in a variety of eukaryotic cells including plants and mammalian cells. The immunoadhesions of the present invention are useful as a therapeutic against the common cold in humans which is caused by rhinoviruses.

Described are a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. Solvents useful for extracting lipids from lipid-containing infectious viral organisms are employed thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. Provided are delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against a lipid-containing infectious viral organism or, as a therapeutic vaccine, to treat or alleviate infection by the lipid-containing infectious viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and / or one or more types of virus.

CRISPR / CAS-related systems, compositions and methods for editing RS1, RL2, and / or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.

A modular waste disinfection system for the disinfection of substantially liquid infectious waste streams and methods of treating such waste streams are disclosed. The modular waste disinfection system includes a metal ion generation chamber for introducing metal ions into the waste material; an oxidant generation chamber in fluid flow communication with the metal ion generation chamber for disinfection of the waste material with an oxidizing agent; and a chelation chamber in fluid flow communication with the oxidant generation chamber for deactivation of metal ions in the waste material, wherein the waste is discharged to a sanitary sewer after disinfection.